Effect of First-Line Ziconotide Intrathecal Drug Therapy for Neuropathic Pain on Disability, Emotional Well-Being, and Pain Catastrophizing
- 1 January 2021
- journal article
- research article
- Published by Elsevier in World Neurosurgery
- Vol. 145, e340-e347
Abstract
No abstract availableKeywords
Funding Information
- Medtronic
- Boston Scientific Corporation
- National Institutes of Health (2R01CA166379-06, U44NS115111)
- Abbott Fund
This publication has 34 references indexed in Scilit:
- Prospective Study of 3-Year Follow-Up of Low-Dose Intrathecal Opioids in the Management of Chronic Nonmalignant PainPain Medicine, 2012
- Pain Catastrophizing: An Updated ReviewIndian Journal of Psychological Medicine, 2012
- Long-term Intrathecal Drug Administration for Chronic Nonmalignant PainJournal of Neurosurgical Anesthesiology, 2012
- Safety and efficacy of intrathecal ziconotide in the management of severe chronic painTherapeutics and Clinical Risk Management, 2009
- Continuous Intrathecal Infusion of Ziconotide for Treatment of Chronic Malignant and Nonmalignant Pain Over 12 Months: A Prospective, Open-label StudyNeuromodulation: Technology at the Neural Interface, 2007
- A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic PainJournal of Pain and Symptom Management, 2006
- Intrathecal Ziconotide in the Treatment of Chronic Nonmalignant Pain: A Randomized, Double-Blind, Placebo-Controlled Clinical TrialNeuromodulation: Technology at the Neural Interface, 2006
- Intrathecal opioid treatment for chronic non-malignant pain: a 3-year prospective studyPain, 2004
- Long-Term Intrathecal Ziconotide Therapy: A Case Study and DiscussionNeuromodulation: Technology at the Neural Interface, 2001
- Comparison of Beck Depression Inventories-IA and-II in Psychiatric OutpatientsJournal of Personality Assessment, 1996